͵ÅÄ͵¿ú

The ͵ÅÄ͵¿ú and ͵ÅÄ͵¿ú Biology has teamed up with to provide ASBMB members fresh industry partnership opportunities each month. Below you'll find several requests for assistance from companies seeking certain expertise and technologies. Learn more about our partnership with Halo.

Bayer Pharma: Human stem cells from patients with genetically derived cardiomyopathy

Bayer Crop Science is seeking stem cells from patients with dilated cardiomyopathies (e.g. laminopathy or others). The genetic defect in those patients causing the disease should be known. They would also need certain clinical parameters of those patients. The cells are not intending to be used for clinical research and development. The deadline for this opportunity is May 31.

Private company: Unique methods to measure intestinal water and cotransporter regulation

This private company is looking to explore and optimize oral rehydration solutions through the utilization of validated intestinal models. The primary objectives involve evaluating the effects of different solution compositions on intestinal water absorption, solute absorption, and their potential to modulate the activity of co-transporters, particularly those responsible for the transport of sugars and amino acids. The deadline for this opportunity is April 30. 

BASF: Biodegradable micro-encapsulation of active ingredients

BASF is seeking a biodegradable encapsulation material for hydrophobic active ingredients. Core-shell morphologies are of high interest, but relevant matrix capsules and other morphologies will be considered. The deadline for this opportunity is April 30.  

Private company: Uncovering the “perfect” natural product from a specific bacteria

This private sponsor is seeking partners who can effectively identify natural project actives derived from a proprietary strain. These identified natural products should demonstrate activity against specific pathogens, while not falling under the categories of antibiotics, siderophores, volatile compounds, unstable polyenes or nonribosomally synthesized peptides. The deadline for this opportunity is April 30.